Literature DB >> 11726558

Dramatic phenotypic improvement during pregnancy in a genetic leukodystrophy: estrogen appears to be a critical factor.

J Matsuda1, M T Vanier, Y Saito, K Suzuki, K Suzuki.   

Abstract

Globoid cell leukodystrophy is one of the classical genetic leukodystrophies in humans. The typical infantile disease in man (Krabbe disease) is caused by deficiency of lysosomal galactosylceramidase. We recently generated a new mouse model of a late-onset, chronic form of the disease by inactivating saposin A, the essential activator of galactosylceramidase. The phenotypic features of saposin A(-/-) mice are qualitatively identical but milder than those of twitcher mice, which is caused by genetic galactosylceramidase deficiency. During intercrossing of saposin A(-/-) mice, we observed that affected females that are continually pregnant showed greatly improved neurological symptoms compared to affected females that do not experience pregnancy, or affected males. The pathological hallmark of globoid cell leukodystrophy, demyelination with infiltration of globoid cells, largely disappeared. The immune-related gene expression (MCP-1, TNF-alpha) was significantly down-regulated in the brain of pregnant saposin A(-/-) mice. In addition, we found intense expression of the estrogen receptors (ER alpha and ER beta) on the globoid cells, activated astrocytes and microglia in the demyelinating area of saposin A(-/-) mice. When saposin A(-/-) mice were subcutaneously implanted with time-release 17 beta-estradiol (E2) pellets from 30 to 90 days, the pathology was vastly improved. These findings suggest that a higher level of estrogen during pregnancy is one of the important factors in the protective effect of pregnancy. While we should be cautious in extrapolating these observations in the mouse to human disease, the phenomenon is spectacularly dramatic and estrogen administration might be worth a consideration as a supplementary treatment for some chronic genetic leukodystrophies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726558     DOI: 10.1093/hmg/10.23.2709

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

Review 1.  Estrogen and testosterone therapies in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

Review 2.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

3.  Estrogen treatment in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  J Neurol Sci       Date:  2009-06-18       Impact factor: 3.181

4.  Isolation of proliferation factor of immature T-cell clone in concanavalin A-stimulated splenocyte culture supernatant.

Authors:  Yasuhiro Kohama; Shinji Shinoda; Katsunobu Hagihara; Takeshi Hashimoto; Asuka Yamaguchi; Akihiro Nakamura; Takahiro Tsuchiya; Kazutake Tsujikawa; Hiroshi Yamamoto
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

5.  17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization.

Authors:  Serena Ghisletti; Clara Meda; Adriana Maggi; Elisabetta Vegeto
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

Review 6.  My journey into the world of sphingolipids and sphingolipidoses.

Authors:  Konrad Sandhoff
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

7.  Sex differences in autoimmune diseases.

Authors:  Rhonda Voskuhl
Journal:  Biol Sex Differ       Date:  2011-01-04       Impact factor: 5.027

8.  Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol.

Authors:  Elisabetta Vegeto; Silvia Belcredito; Sabrina Etteri; Serena Ghisletti; Alessia Brusadelli; Clara Meda; Andrée Krust; Sonia Dupont; Paolo Ciana; Pierre Chambon; Adriana Maggi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.